SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate Risk NMIBC – UroToday

Written by

admin

in

  1. SCS AUA 2025: Trial in Progress: PIVOT-006 – a Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate Risk NMIBC  UroToday
  2. CG Oncology (CGON): Assessing Valuation Following Landmark 24-Month BOND-003 Results for Bladder Cancer Therapy  simplywall.st
  3. Enrollment goal met in PIVOT-006 trial of cretostimogene grenadenorepvec in IR-NMIBC  Urology Times
  4. CG Oncology stock holds Buy rating at H.C. Wainwright on strong cancer data  Investing.com
  5. Cantor Fitzgerald Reiterates Overweight Rating for CG Oncology (NASDAQ:CGON)  MarketBeat

Continue Reading

More posts